Investor Relations 2021

1Q21 Business Results Income Statement Revenue Rise in sales of Remsima", Herzuma®, and RemsimaⓇ SC offset temporary decrease in US sales attributable to shipment schedule ▶ OP : Decreased QoQ as a result of a scheuled decline in high-margin US TruximaⓇ sales as well as rises in SG&A for direct sales NP Recorded similar net profit YoY with increases in non-operating profit as won weakened compared to the previous quarter (KRW bn) '20.1Q '20.4Q '21.1Q % YoY %QoQ Revenue 356.9 387.0 356.3 -0.2% -7.9% Gross Profit 94.5 145.0 82.3 -12.9% -43.2% (%) 26.5% 37.5% 23.1% -3.4%p -14.4%p SG&A 38.7 53.3 50.8 31.3% -4.7% (%) 10.8% 13.8% 14.3% 3.5%p 0.5%p Personnel expenses 6.8 16.9 12.8 88.2% -24.3% Research expenses 6.4 7.9 9.8 53.1% 24.1% Advertising expenses 2.5 2.4 1.4 -44.0% -41.7% Commissions 9.4 13.7 13.4 42.6% -2.2% Operating Profit 55.8 91.8 31.5 -43.5% -65.7% (%) 15.6% 23.7% 8.8% -6.8%p -14.9%p EBIT 98.2 27.2 35.0 -64.4% 28.7% Net Profit 76.2 31.7 31.5 -58.7% -0.6% Investor Relations 2021 4

View entire presentation